Cargando…
COVID-19 phenotypes: leading or misleading?
Comment on the editorial by Bos et al. about “perils of premature phenotyping in COVID-19”, querying the risks of COVID-19 phenotypes and how the arguments put forward can further the cause of patients and clinicians https://bit.ly/2Y6VZz9
Autores principales: | Gattinoni, Luciano, Camporota, Luigi, Marini, John J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331647/ https://www.ncbi.nlm.nih.gov/pubmed/32616591 http://dx.doi.org/10.1183/13993003.02195-2020 |
Ejemplares similares
-
Response to COVID-19 phenotyping correspondence
por: Bos, Lieuwe D.J., et al.
Publicado: (2020) -
mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
por: Tang, Yan, et al.
Publicado: (2021) -
COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness
por: Cherian, Robin, et al.
Publicado: (2020) -
On tuberculosis and COVID-19 co-infection
por: Tadolini, Marina, et al.
Publicado: (2020) -
The effect of catch-up growth in the first year of life on later wheezing phenotypes
por: Kotecha, Sarah J., et al.
Publicado: (2020)